KALRAY
Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage.
Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this growth. Storage is one major bottleneck of the increasing performance needs in Data Centers, driving the introduction of flash technology-based drives (“Solid-State Drive” or SSD) with hyper-fast communication protocols such as NVMe® and NVMe-oF™.
FURIO1200™, as an NVMe-oF all flash JBOF (“Just Bunch of Flash”) appliance, offers a breakthrough solution for the industry to massively scale up and increase performance of existing data centers. In addition, FURIO1200™ makes disaggregation a reality, by allowing compute resources to be separated from storage resources while optimizing performance of the overall system and re-use.
Eric Baissus, President and CEO of Kalray , has declared: “Together with WISTRON, one of the world’s largest manufacturers of data center servers, we are very proud of our contribution to development of the FURIO1200™ solution. We expect this solution to become a game changer in the industry .”
William Lin, President of Enterprise Business Group of Wistron Technologies, Wistron Corporation, has declared: “We are enthused about FURIO1200™ availability. There is a strong need for more efficient and scalable storage solutions in the market. It’s the perfect fit for data intensive applications such as AI, data analytics or IoT, for increasing performance of existing datacenters as well as addressing the growing markets of hyper converged infrastructure and on-premises enterprise data centers.”
Whereas most storage platforms run standard x86 processor, FURIO1200™ is powered by Kalray MPPA® Coolidge™ Intelligent Processor. The MPPA® processor has been designed to manage in parallel a huge flow of data in real time and removes the traditional bottleneck in running intensive data services such as data protection on intense workloads. This results in unique performance improvements and a reduction of the workload on the servers connected to FURIO1200™, freeing expensive resources for data center users.
FURIO1200™ will be available for Proof of Concept (PoC) first quarter of this year, and targets volume production by mid 2021, first customer trials being planned in the coming weeks.
FURIO1200™ is a 2U chassis using Gen3 PCIe fabric, featuring comprehensive chassis management with redundant and efficient power provision and is able to host 24 U.2 NVMe SSDs and multiple PCIe K200™ Coolidge™- based smart storage adapter solutions. FURIO1200™ delivers more than 12 million IOPS (Input/Output Operations per second) within a range of 20 to 50us latency and a global throughput of up to 72GB/s whilst supporting in parallel data protection services such as Erasure Coding.
FURIO1200™ integrates Kalray K200™ cards running NVMe-oF Kalray software, which has been certified by the University of New Hampshire InterOperability Laboratory (UNH-IOL), an independent testing provider of standard conformance solutions and multi-vendor interoperability.
One additional specialty of FURIO1200™ is the seamless support of the NVMe-over Fabric (“NVMe-oF”) over RDMA (“RDMA over Converged Ethernet” or RoCE) or over TCP protocol standards. This dual-persona capability brings the flexibility required in evolving data centers, minimizing investment while maximizing the return and lifetime of the FURIO1200™-based infrastructure.
In addition, the Intelligent Processors integrated into Kalray cards are fully programmable and are provided with an open SDK. This makes FURIO1200™ an evolving, customizable and future proof solution. New software releases are planned with additional features such as KVS, in-line security services offloading (e.g. SSL-TLS or IPSEC), computational storage, and AI analytics as well cluster storage support.
About Wistron
Wistron Corporation is a Fortune® Global 500™company supplying the design, manufacturing and after-sales services on various ICT (information and communication technology) products to top branded companies worldwide. Wistron’s product and service lines include PCs, server and networking systems, enterprise storage solutions, professional display products, communication devices, after-sales services, and electronics scrap recycling, as well as cloud and display vertical integration solutions. With the development of cloud computing, Wistron combines hardware devices and cloud data systems through software services to provide technical service platforms and solutions to our customers. In addition, Wistron has been dedicated to building value chain in ICT industry and innovation platforms in the new era of education and enterprise services, IOT, and medical services. For more information, please visit: www.wistron.com .
About Kalray
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, leading provider in a new generation of processors specialized in Intelligent Data Processing from Cloud to Edge. Kalray MPPA® Intelligent Processors are able to capture and analyze on the fly massive data flows, and interact in real time with the outside world. These processors are capable of running demanding AI algorithms and simultaneously a wide set of different processing and control tasks such as intensive mathematical algorithms, signal processing, network or storage software stacks. Kalray’s Intelligent Processors can be deployed in fast-growing sectors from Cloud to Edge: modern data centers, 5G telecom networks, autonomous vehicles, healthcare equipment, industry 4.0, drones and robots… Kalray’s offering includes processors, acceleration cards and a software suite, for a broad spectrum of customers such as next generation data center equipment manufacturers and service providers, system integrators and consumer product manufacturers such as car makers. Founded in 2008 as a spin-off of CEA French lab, Kalray counts among its investors: Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance.
Read more at: www.kalrayinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005644/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom